Adults Hospitalized With Coronavirus Disease 2019 (COVID-19)-United States, March-June and October-December 2020: Implications for the Potential Effects of COVID-19 Tier-1 Vaccination on Future Hospitalizations and Outcomes.
COVID-19
SARS-CoV-2
United States
hospitalization
vaccination
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 07 2021
15 07 2021
Historique:
pubmed:
13
5
2021
medline:
21
7
2021
entrez:
12
5
2021
Statut:
ppublish
Résumé
Because of the increased risk for severe coronavirus disease 2019 (COVID-19), the Advisory Committee on Immunization Practices (ACIP) initially prioritized COVID-19 vaccination for persons in long-term care facilities (LTCF), persons aged ≥65 years, and persons aged 16-64 years with high-risk medical conditions when there is limited vaccine supply. We compared characteristics and severe outcomes of hospitalized patients with COVID-19 in the United States between early and later in the pandemic categorized by groups at higher risk of severe COVID-19. Observational study of sampled patients aged ≥18 years who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and admitted to one of 14 academic hospitals in the United States during March-June and October-December 2020. Demographic and clinical information were gathered from electronic health record data. Among 647 patients, 91% met ≥1 of the following risk factors for severe COVID-19 [91% March-June (n = 434); 90% October-December (n = 213)]; 19% were LTCF residents, 45% were aged ≥65-years, and 84% had ≥1 high-risk condition. The proportion of patients who resided in a LTCF declined significantly (25% vs 6%) from early to later pandemic periods. Compared with patients at lower risk for severe COVID-19, in-hospital mortality was higher among patients at high risk for severe COVID-19 (20% vs 7%); these differences were consistently observed between March-June and October-December. Most adults hospitalized with COVID-19 were those recommended to be prioritized for vaccination based on risk for developing severe COVID-19. These findings highlight the continued urgency to vaccinate patients at high risk for severe COVID-19 and monitor vaccination impact on hospitalizations and outcomes.
Sections du résumé
BACKGROUND
Because of the increased risk for severe coronavirus disease 2019 (COVID-19), the Advisory Committee on Immunization Practices (ACIP) initially prioritized COVID-19 vaccination for persons in long-term care facilities (LTCF), persons aged ≥65 years, and persons aged 16-64 years with high-risk medical conditions when there is limited vaccine supply. We compared characteristics and severe outcomes of hospitalized patients with COVID-19 in the United States between early and later in the pandemic categorized by groups at higher risk of severe COVID-19.
METHODS
Observational study of sampled patients aged ≥18 years who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and admitted to one of 14 academic hospitals in the United States during March-June and October-December 2020. Demographic and clinical information were gathered from electronic health record data.
RESULTS
Among 647 patients, 91% met ≥1 of the following risk factors for severe COVID-19 [91% March-June (n = 434); 90% October-December (n = 213)]; 19% were LTCF residents, 45% were aged ≥65-years, and 84% had ≥1 high-risk condition. The proportion of patients who resided in a LTCF declined significantly (25% vs 6%) from early to later pandemic periods. Compared with patients at lower risk for severe COVID-19, in-hospital mortality was higher among patients at high risk for severe COVID-19 (20% vs 7%); these differences were consistently observed between March-June and October-December.
CONCLUSIONS
Most adults hospitalized with COVID-19 were those recommended to be prioritized for vaccination based on risk for developing severe COVID-19. These findings highlight the continued urgency to vaccinate patients at high risk for severe COVID-19 and monitor vaccination impact on hospitalizations and outcomes.
Identifiants
pubmed: 33977301
pii: 6270754
doi: 10.1093/cid/ciab319
pmc: PMC8136001
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
S32-S37Subventions
Organisme : NIAID NIH HHS
ID : K24 AI148459
Pays : United States
Organisme : NIGMS NIH HHS
ID : K23 GM129661
Pays : United States
Organisme : NIH HHS
Pays : United States
Organisme : NCATS NIH HHS
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000445
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Références
MMWR Morb Mortal Wkly Rep. 2020 Jul 10;69(27):882-886
pubmed: 32644985
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):790-794
pubmed: 32584797
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
MMWR Morb Mortal Wkly Rep. 2020 Oct 02;69(39):1404-1409
pubmed: 33001872
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657-1660
pubmed: 33382671
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
MMWR Morb Mortal Wkly Rep. 2020 Aug 11;69(32):1095-1099
pubmed: 32790655
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):841-846
pubmed: 32614810